Wall Street analysts changed outlook on top names. For full changes, see our analyst ratings page. Analysts have mixed opinions on SCHW stock.
Compass Point, BTIG, Wells Fargo initiate coverage: Schwab (Buy, $135), Yarrow Bio (Buy, $58), Pyxis (Overweight, $12). Bullish consensus on fintech and biotech signals M&A wave; tech leaders must accelerate platform integration and API partnership strategy.
Top Wall Street analysts changed their outlook on these top names.
For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Compass Point analyst Ed Engel initiated coverage on Charles Schwab Corporation (NYSE:SCHW) with a Buy rating and announced a price target of $135.
Charles Schwab closed at $105.24 on Friday.
See how other analysts view this stock.
Wall Street analysts change ratings on top stocks. See full changes on analyst ratings page. SCHW, MNST, FDUS have new outlooks.
Wall Street analysts changed outlook on top names. For full changes, upgrades, downgrades and initiations, see analyst ratings…
Top Wall Street analysts changed outlook on top names. Analyst rating changes include upgrades, downgrades, and initiations. See…
Truist Financial analyst Brian Foran maintained a Buy rating on Charles Schwab yesterday and set a price target of…
Charles Schwab (NYSE: SCHW) beats Q2 2026 earnings & revenue estimates as revenue grows 21% to $7.07B. Full results breakdown…
Wall Street analysts change outlook for top stocks. See upgrades, downgrades, and initiations on analyst ratings page. HSIC stock…
